Ovid Therapeutics Inc. (OVID): Capital Expenditures
$0
Year ended 2025-12-31
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $0 | -100.0% | 2026-03-18, From 2025-01-01 |
| 2024-12-31 | $71.0K | +77.5% | 2026-03-18, From 2024-01-01 |
| 2023-12-31 | $40.0K | -96.7% | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | $1.22M | +565.4% | 2024-03-08, From 2022-01-01 |
| 2021-12-31 | $184.0K | +44.6% | 2023-03-13, From 2021-01-01 |
| 2020-12-31 | $127.2K | +122.6% | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | $57.2K | +68.7% | 2021-03-15, From 2019-01-01 |
| 2018-12-31 | $33.9K | -12.9% | 2020-03-11, From 2018-01-01 |
| 2017-12-31 | $38.9K | +28.1% | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | $30.4K | -5.4% | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | $32.1K | n/a | 2018-03-29, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗